Is there public comment at the Drug Utilization Review (DUR) Board and Therapeutics Committee meetings?
See the Drug Utilization Review Board page. For the Therapeutics Committee: The time remaining at the end of Meeting 1 will be allocated for public comment. Comment will be limited to two speakers per product and one minute per speaker. Speakers may only present new product information (changes since the last review) or new products. There will only be one sign-in sheet for speakers. There will not be a sign-in sheet for each class. The sign-in sheet will be available the morning of the meeting.
Is there public comment at the Drug Utilization Review (DUR) Board and Therapeutics Committee meetings?